Compositions And Methods For Macular Degeneration
AssigneeThe Cleveland Clinic Foundation and Case Western Reserve University
InventorsJohn W. Crabb, Robert G. Salomon, Bela Anand-Apte, Quteba Ebrahem, Kutralanathan Renganathan
Life of this patent
Estimating the term…
Abstract
The present invention pertains to methods of inhibiting angiogenesis (e.g., ocular angiogenesis choroidal neovasculariztion) in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of 5 oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual.
Claims51
A method of inhibiting angiogenesis in an individual in need thereof, comprising administering to the individual an agent that inhibits one or more carboxyethylpyrrole (CEP) protein adducts, wherein the angiogenesis is the result of oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual.
A method of inhibiting ocular angiogenesis in an individual in need thereof, comprising administering to the individual an agent that inhibits one or more carboxyethylpyrrole (CEP) protein adducts wherein administration of the agent inhibits ocular angiogenesis in the individual.
A method of inhibiting choroidal neovascularization in an individual in need thereof, comprising administering to the individual an agent that inhibits one or more carboxyethylpyrrole (CEP) protein adducts wherein administration of the agent inhibits choroidal neovascularization in the individual.
A method of treating age-related macular degeneration (AMD) in an individual in need thereof, comprising administering to the individual an agent that inhibits one or more carboxyethylpyrrole (CEP) protein adducts in the individual, thereby treating the AMD.
Use of an agent that inhibits one or more carboxyethylpyrrole (CEP) protein adducts in the manufacture of a medicament for inhibiting angiogenesis, wherein the angiogenesis is the result of oxidative peptide modification of polyunsaturated fatty acids (PUFA).
Use of an agent that inhibits one or more carboxyethylpyrrole (CEP) protein adducts in the manufacture of a medicament for inhibiting ocular angiogenesis.
Use of an agent that inhibits one or more carboxyethylpyrrole (CEP) protein adducts in the manufacture of a medicament for inhibiting choroidal neovascularization.
Use of an agent that inhibits one or more carboxyethylpyrrole (CEP) protein adducts in the manufacture of a medicament for treating age-related macular degeneration (AMD).
Dependencies are inferred from the claim text.